In a nutshell This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumab (Cyramza) and pembrolizumab (Keytruda) works better than standard care practices. The main outcome that will be measured is the overall survival rates. This study will take place in the United States. The details There are a...
Read MoreType of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Using blood test results to predict survival in non-small cell lung cancer
In a nutshell This study wanted to find out if certain levels of compounds in the blood could predict survival in patients with non-small cell lung cancer (NSCLC). The study found that levels of some of the compounds tested were related to how well the patients survived. Some background The levels of certain compounds in the blood are tested...
Read MoreEvaluating osimertinib for elderly patients over age 80 with advanced NSCLC
In a nutshell This study evaluated the effectiveness of osimertinib (Tagrisso) in patients over age 80 with advanced small cell lung cancer (NSCLC). This study found that these elderly patients had similar outcomes to patients in clinical trials. Some background NSCLC is the most common type of lung cancer. One common treatment is...
Read MoreSafety and efficacy of stereotactic body radiotherapy for centrally located non-small cell lung cancer
In a nutshell This article investigated the safety and effectiveness of stereotactic body radiotherapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). The authors concluded that SBRT is safe and effective for these patients. Some background NSCLC is the most common kind of lung cancer. Patients with...
Read MoreLocal consolidative therapy – does this improve survival in advanced lung cancer?
In a nutshell This study investigated the effect of local consolidative therapy (LCT) with radiotherapy or surgery in patients with advanced non-small cell lung cancer (NSCLC). They found that LCT prolonged survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Metastatic...
Read MoreLooking for patients with non-small cell lung cancer to test a new immunotherapy combination
In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...
Read MoreSearching for patients with non-small cell lung cancer suitable for surgery to test durvalumab with chemotherapy
In a nutshell This phase 3 trial is examining the effectiveness of durvalumab (Imfinzi) combined with chemotherapy vs chemotherapy alone for stage II and III non-small cell lung cancer (NSCLC) before surgery. The main outcome to be measured will be the major pathological response (mPR; 10 percent or fewer alive cancer cells...
Read MoreIs combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?
In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....
Read MoreChemotherapy and radiotherapy alongside treatment with cetuximab for non-small cell lung cancer
In a nutshell This study evaluated the effectiveness of adding cetuximab (Erbitux) to standard chemotherapy and radiotherapy treatment for advanced non-small cell lung cancer (NSCLC). This study found that adding cetuximab to chemotherapy and radiotherapy resulted in promising outcomes. Some background NSCLC is the...
Read MoreEvaluating crizotinib for patients with non-small cell lung cancer that has spread to the brain
In a nutshell This study evaluated how well crizotinib (Xalkori) works in patients with non-small cell lung cancer (NSCLC) with an ALK mutation that had spread to the brain. This study found that crizotinib treatment improved survival, but not for patients with cancer in the brain that continued to grow. Some background NSCLC is the most common type...
Read MoreIs crizotinib an effective treatment for advanced non-small cell lung cancer?
In a nutshell This study investigated the safety and effectiveness of crizotinib (Xalkori) in advanced non-small cell lung cancer (NSCLC). They found that this treatment improved survival in advanced NSCLC. Some background Standard therapy for NSCLC involves chemotherapy and radiation. Patients with advanced NSCLC may not respond to...
Read MoreSecond-line therapy for lung cancer – which is most effective?
In a nutshell This study investigated second-line treatments for non-small cell lung cancer (NSCLC). They found that second-line options are effective in advanced NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many cases of NSCLC are diagnosed at an advanced stage. First-line treatment...
Read More
